Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

Gastroenterology

Volumn 139, Issue 3, 2010, Pages

  Öberg, Kjell E ^a   Reubi, Jeanclaude ^b   Kwekkeboom, Dik J ^c   Krenning, Eric P ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BERN   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Peptide Radio Receptor Therapy; Somatostatin Analogs; Somatostatin Receptors

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; BIM 23A760; DOPAMINE 2 RECEPTOR; EVEROLIMUS; G PROTEIN COUPLED RECEPTOR; KE 108; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PEGINTERFERON; PENTETREOTIDE IN 111; PLACEBO; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; VAPREOTIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; INCIDENCE; INJECTION SITE PAIN; ISOTOPE LABELING; MONOTHERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PANCREAS TUMOR; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; GASTROINTESTINAL NEOPLASMS; METABOLISM; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84925581799     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.07.002     Document Type: Review

References (96)

1. R. Guillemin Hypothalamic hormones a.k.A. hypothalamic releasing factors J Endocrinol 184 2005 11 28
2. S. Pyronnet, C. Bousquet, and S. Najib Antitumor effects of somatostatin Mol Cell Endocrinol 286 2008 230 237
3. L. de Lecea, and J.P. Castano Cortistatin: not just another somatostatin analog Nat Clin Pract Endocrinol Metab 2 2006 356 357
4. G. Weckbecker, I. Lewis, and R. Albert Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat Rev Drug Discov 2 2003 999 1017
5. G. Olias, C. Viollet, and H. Kusserow Regulation and function of somatostatin receptors J Neurochem 89 2004 1057 1091
6. R. DeLellis, R. Lloyd, and P.U. Heitz World Health Organisation Classification of Tumors Pathology and genetics: tumor of endocrine organs 2004 IARC Press Lyon Cedex 08, France 185 190
7. N. Garbrecht, M. Anlauf, and A. Schmitt Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity Endocr Relat Cancer 15 2008 229 241
8. E. Allia, E. Tarabra, and M. Volante Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours J Pathol 207 2005 336 345
9. J.C. Reubi, and A.M. Landolt High density of somatostatin receptors in pituitary tumors from acromegalic patients J Clin Endocrinol Metab 59 1984 1148 1151
10. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 2003 389 427
11. M. Korner, V. Eltschinger, and B. Waser Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography Am J Surg Pathol 29 2005 1642 1651
12. M. Volante, M.P. Brizzi, and A. Faggiano Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy Mod Pathol 20 2007 1172 1182
13. T. Fischer, C. Doll, and S. Jacobs Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 J Clin Endocrinol Metab 93 2008 4519 4524
14. J.C. Reubi, B. Waser, and R. Cescato Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients J Clin Endocrinol Metab 95 2010 2343 2350
15. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 2003 781 793
16. J.C. Reubi, L.K. Kvols, and B. Waser Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas Cancer Res 50 1990 5969 5977
17. J.C. Reubi, L. Mazzucchelli, and I. Hennig Local up-regulation of neuropeptide receptors in host blood vessels around human colorectal cancers Gastroenterology 110 1996 1719 1726
18. J.C. Reubi, L. Mazzucchelli, and J.A. Laissue Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease Gastroenterology 106 1994 951 959
19. A. Schonbrunn Somatostatin receptors V. Lennarz, M. Lane, Encyclopedia of biological chemistry Volume 4 2004 Elsevier Oxford, England
20. K. Sharma, and C.B. Srikant Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells Int J Cancer 76 1998 259 266
21. E.A. Woltering Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives Cancer Biother Radiopharm 18 2003 601 609
22. M.C. Zatelli, D. Piccin, and C. Vignali Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion Endocr Relat Cancer 14 2007 91 102
23. L. Bodei, G. Paganelli, and G. Mariani Receptor radionuclide therapy of tumors: a road from basic research to clinical applications J Nucl Med 47 2006 375 377
24. M. van Essen, E. Krenning, and B. Kam Peptide-receptor radionuclide therapy for endocrine tumors Nat Rev Endocrinol 5 2009 382 393
25. R. Cescato, S. Schulz, and B. Waser Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists J Nucl Med 47 2006 502 511
26. Q. Liu, R. Cescato, and D.A. Dewi Receptor signaling and endocytosis are differentially regulated by somatostatin analogs Mol Pharmacol 68 2005 90 101
27. M. Ginj, J. Chen, and M.A. Walter Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy Clin Cancer Res 11 2005 1136 1145
28. B. Waser, M.L. Tamma, and R. Cescato Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues J Nucl Med 50 2009 936 941
29. M. Ginj, H. Zhang, and B. Waser Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors Proc Natl Acad Sci U S A 103 2006 16436 16441
30. T. Stroh, A.C. Jackson, and P. Sarret Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis Endocrinology 141 2000 354 365
31. S.P. Rohrer, E.T. Birzin, and R.T. Mosley Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry Science 282 1998 737 740
32. R. Cescato, K.A. Loesch, and B. Waser Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways Mol Endocrinol 24 2009 240 249
33. J.C. Reubi, and H.R. Maecke Peptide-based probes for cancer imaging J Nucl Med 49 2008 1735 1738
34. M. Ginj, H. Zhang, and K.P. Eisenwiener New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting Clin Cancer Res 14 2008 2019 2027
35. Wild D, Fani M, Behe M, et al. First clinical evaluation of somatostatin receptor antagonist imaging. Presented at: 57th Annual Meeting of the Society of Nuclear Medicine; June 8, 2010; Salt Lake City, UT.
36. R. Cescato, J. Erchegyi, and B. Waser Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting J Med Chem 51 2008 4030 4037
37. W. Bauer, U. Briner, and W. Doepfner SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1982 1133 1140
38. I. Lancranjan, C. Bruns, and P. Grass Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients Metabolism 45 1996 67 71
39. P. Caron, I. Morange-Ramos, and M. Cogne Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide J Clin Endocrinol Metab 82 1997 18 22
40. R.Z. Cai, B. Szoke, and R. Lu Synthesis and biological activity of highly potent octapeptide analogs of somatostatin Proc Natl Acad Sci U S A 83 1986 1896 1900
41. C. Bruns, I. Lewis, and U. Briner SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 2002 707 716
42. L.J. Hofland, and S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 2003 28 47
43. E. Lohof, E. Planker, and C. Mang Carbohydrate derivatives for use in drug design: cyclic alpha(v)-selective RGD peptides Angew Chem Int Ed Engl 39 2000 2761 2764
44. K. Oberg, L. Kvols, and M. Caplin Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Ann Oncol 15 2004 966 973
45. R. Srirajaskanthan, J. Watkins, and L. Marelli Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies Neuroendocrinology 89 2009 308 314
46. P. Jaquet, G. Gunz, and A. Saveanu BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide J Endocrinol Invest 28 2005 21 27
47. S.M. Wood, M.E. Kraenzlin, and T.E. Adrian Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses Gut 26 1985 438 444
48. L.K. Kvols, C.G. Moertel, and M.J. O'Connell Treatment of the malignant carcinoid syndrome Evaluation of a long-acting somatostatin analogue N Engl J Med 315 1986 663 666
49. P. Gorden, R.J. Comi, and P.N. Maton NIH conference Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut Ann Intern Med 110 1989 35 50
50. I.M. Modlin, M. Pavel, and M. Kidd Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Aliment Pharmacol Ther 31 2010 169 188
51. E. Bajetta, G. Procopio, and L. Catena Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study Cancer 107 2006 2474 2481
52. S. Ricci, A. Antonuzzo, and L. Galli Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors Am J Clin Oncol 23 2000 412 415
53. B. Eriksson, and K. Oberg Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook Ann Oncol 10 Suppl 2 1999 S31 S38
54. Kvols LK, Oberg K, Glusman JE, et al. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to Octreotide LAR: results of a phase II study. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 26, 2006; Atlanta, GA.
55. M.A. Kinney, M.E. Warner, and D.M. Nagorney Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours Br J Anaesth 87 2001 447 452
56. H.A. Kharrat, and H. Taubin Carcinoid crisis induced by external manipulation of liver metastasis J Clin Gastroenterol 36 2003 87 88
57. L. Saltz, B. Trochanowski, and M. Buckley Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 72 1993 244 248
58. U. Plockinger, and B. Wiedenmann Neuroendocrine tumors Biotherapy Best Pract Res Clin Endocrinol Metab 21 2007 145 162
59. S.V. Welin, E.T. Janson, and A. Sundin High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours Eur J Endocrinol 151 2004 107 112
60. S. Faiss, U. Rath, and U. Mansmann Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 1999 469 476
61. D. Granberg, H. Jacobsson, and K. Oberg Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report Digestion 77 2008 92 95
62. A. Rinke, H.H. Muller, and C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
63. E.T. Janson, and K. Oberg Long-term management of the carcinoid syndrome Treatment with octreotide alone and in combination with alpha-interferon Acta Oncol 32 1993 225 229
64. L. Kolby, G. Persson, and S. Franzen Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 2003 687 693
65. R. Arnold, A. Rinke, and K.J. Klose Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
66. J.C. Yao, A. Phan, and P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 2008 1316 1323
67. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154
68. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol;28:6976.
69. E.P. Krenning, D.J. Kwekkeboom, and W.H. Bakker Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716 731
70. I. Buchmann, M. Henze, and S. Engelbrecht Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 2007 1617 1626
71. R. Valkema, M. De Jong, and W.H. Bakker Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience Semin Nucl Med 32 2002 110 122
72. L.B. Anthony, E.A. Woltering, and G.D. Espenan Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies Semin Nucl Med 32 2002 123 132
73. A. Otte, R. Herrmann, and A. Heppeler Yttrium-90 DOTATOC: first clinical results Eur J Nucl Med 26 1999 1439 1447
74. C. Waldherr, M. Pless, and H.R. Maecke The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann Oncol 12 2001 941 945
75. C. Waldherr, M. Pless, and H.R. Maecke Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC J Nucl Med 43 2002 610 616
76. C. Waldherr, T. Schumacher, and H.R. Maecke Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29 2002 100
77. M. Chinol, L. Bodei, and M. Cremonesi Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group Semin Nucl Med 32 2002 141 147
78. G. Paganelli, L. Bodei, and D. Handkiewicz Junak 90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies Biopolymers 66 2002 393 398
79. L. Bodei, M. Cremonesi, and S. Zoboli Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study Eur J Nucl Med Mol Imaging 30 2003 207 216
80. R. Valkema, S. Pauwels, and L.K. Kvols Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors Semin Nucl Med 36 2006 147 156
81. R. Valkema, S. Pauwels, and L. Kvols Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3] octreotide in patients with somatostatin receptor positive tumours Eur J Nucl Med Mol Imaging 30 2003 232
82. D.L. Bushnell Jr, T.M. O'Dorisio, and M.S. O'Dorisio 90Y-edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
83. J.C. Reubi, J.C. Schar, and B. Waser Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 2000 273 282
84. 177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
85. 177Lu-DOTA0,Tyr3]octreotate Eur J Nucl Med Mol Imaging 35 2008 749 755
86. T.E. Clancy, T.P. Sengupta, and J. Paulus Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors Dig Dis Sci 51 2006 877 884
87. E.T. Janson, L. Holmberg, and M. Stridsberg Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center Ann Oncol 8 1997 685 690
88. P.F. Quaedvlieg, O. Visser, and C.B. Lamers Epidemiology and survival in patients with carcinoid disease in The Netherlands An epidemiological study with 2391 patients Ann Oncol 12 2001 1295 1300
89. P.J. Mazzaglia, E. Berber, and M. Milas Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival Surgery 142 2007 10 19
90. van Essen M, Krenning EP, Kam BL, et al. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med;51:383390.
91. M. De Jong, R. Valkema, and F. Jamar Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 2002 133 140
92. T.A. Rich, R.C. Shepard, and S.T. Mosley Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy J Clin Oncol 22 2004 2214 2232
93. J. Dunst, T. Reese, and T. Sutter Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer J Clin Oncol 20 2002 3983 3991
94. 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 35 2008 743 748
95. 177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo]octreotide in patients Eur J Nucl Med 28 2001 1319 1325
96. 177Lu-DOTA(0),Tyr(3)]octreotate Eur J Nucl Med Mol Imaging 36 2009 1138 1146